EPISODE · May 27, 2026 · 4 MIN
Outlook Wins Appeal for Wet AMD Drug Candidate Lytenava
from Eyewire News: The Podcast · host Eyewire News
Outlook Therapeutics takes a major step forward in its plan to gain approval for wet AMD drug Lytenava; the first commercial FLIGHT procedures using the ViaLuxe Laser System are performed in Europe; and Oculus introduces a new AI-assisted tool designed to help clinicians evaluate MGD using meibography images. Learn more about your ad choices. Visit megaphone.fm/adchoices
What this episode covers
Outlook Therapeutics takes a major step forward in its plan to gain approval for wet AMD drug Lytenava; the first commercial FLIGHT procedures using the ViaLuxe Laser System are performed in Europe; and Oculus introduces a new AI-assisted tool designed to help clinicians evaluate MGD using meibography images. Learn more about your ad choices. Visit megaphone.fm/adchoices
NOW PLAYING
Outlook Wins Appeal for Wet AMD Drug Candidate Lytenava
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m